Timeline
Nathalie Jolly
Head of Facility
15 Mar 2023
project
CoVariant – Comprendre les déterminants de l’immunité muqueuse et optimiser le diagnostic de l’infection aux variants du SARS-CoV-2
Read more15 Mar 2023
project
Études nécessitant l’accès aux données du Système National des Données de Santé (SNDS).
Read more04 Jan 2023
news
PREGASIGN: Signatures de biomarqueurs circulants pour la détection des lésions de prénéoplasie et de cancer gastrique
Read more01 Sep 2022
publication
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
Read more07 Feb 2022
project
Ressources for good practices in implementing clinical research and translational research on human samples and data
Read more01 Jan 2022
publication
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Read more16 Jul 2021
01 Apr 2021
publication
SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020
Read more06 Nov 2020
news
Suivi de la persistance de la réponse immunitaire contre le SARS-CoV-2 au sein de la cohorte de Crépy-en-Valois (COVID-Oise)
Read more02 Sep 2020
publication
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Read more01 Sep 2020
publication
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.
Read more26 Jun 2020
25 Jun 2018
21 Jul 2015
09 Jan 2009
publication
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial
Read more03 Dec 2007
publication
Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers
Read more01 Aug 2003
publication